Similar articles

• Bone marrow transplantation for acute lymphoblastic leukaemia in first and second remission.

  Barrett AJ, Horowitz MM, McCarthy DM, Kanfer E, Bortin MM. Barrett AJ, et al. Bone Marrow Transplant. 1989 Jan;4 Suppl 1:247-9. Bone Marrow Transplant. 1989. PMID: 2653514 Review. No abstract available.
• Autologous marrow transplantation in acute lymphoblastic leukemia: control of residual disease with mafosfamide and induction of syngeneic GVHD with cyclosporin. The Italian Mafosfamide Study Group.

  Rizzoli V, Carella AM, Carlo-Stella C, Mangoni L. Rizzoli V, et al. Bone Marrow Transplant. 1990 Jul;6 Suppl 1:76-8. Bone Marrow Transplant. 1990. PMID: 2202474 Clinical Trial. No abstract available.
• Busulphan, cyclophosphamide, and melphalan as conditioning therapy in allogeneic bone marrow transplants for acute lymphoblastic leukemia.

  Russell S, Vowels M. Russell S, et al. Transplant Proc. 1992 Feb;24(1):183. Transplant Proc. 1992. PMID: 1539236 Clinical Trial. No abstract available.
• Allogeneic BMT for AML in Zagreb.

  Labar B, Bogdanić V, Nemet D, Mrsić M, Pavletić Z, Zupancić S, Radman I, Aurer I. Labar B, et al. Bone Marrow Transplant. 1989 Dec;4 Suppl 3:86-7. Bone Marrow Transplant. 1989. PMID: 2697413 Clinical Trial. No abstract available.
• Allogeneic versus autologous bone marrow transplantation versus intensive post-remission chemotherapy in acute leukaemias.

  Bernasconi C, Lazzarino M, Canevari A, Morra E, Castelli G, Brusamolino E, Alessandrino EP, Pagnucco G, Orlandi E, Castagnola C, et al. Bernasconi C, et al. Bone Marrow Transplant. 1989 Dec;4 Suppl 4:65-8. Bone Marrow Transplant. 1989. PMID: 2697439 Review. No abstract available.